for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Atrion Corporation

ATRI.OQ

Latest Trade

--

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

--

 - 

--

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
--
Open
--
Volume
--
3M AVG Volume
0.37
Today's High
--
Today's Low
--
52 Week High
--
52 Week Low
--
Shares Out (MIL)
1.85
Market Cap (MIL)
1,295.67
Forward P/E
--
Dividend (Yield %)
0.89

Next Event

Q4 2019 Atrion Corp Earnings Release

Latest Developments

More

Atrion Posts Q3 EPS Of $5.15

Atrion Corporation Increases Quarterly Cash Dividend By 15%

Atrion Q2 Earnings Per Share $5.18

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Atrion Corporation

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company's medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology. Its cardiovascular product, MPS2 Myocardial Protection System (MPS2), is the system used in open-heart surgery that delivers fluids and medications, mixes critical drugs and controls temperature, pressure and other variables. The Company manufactures specialized medical devices that disinfect contact lenses. Its other medical and non-medical product lines consist of instrumentation and associated disposables.

Industry

Medical Equipment & Supplies

Contact Info

1 Allentown Pkwy

+1.972.3909800

http://www.atrioncorp.com/

Executive Leadership

Emile A. Battat

Chairman of the Board

David A. Battat

President, Chief Executive Officer

Jeffery Andrew Strickland

Chief Financial Officer, Vice President, Treasurer, Secretary

Preston G. Athey

Independent Director

Hugh J. Morgan

Independent Director

Key Stats

Price To Earnings (TTM)
35.69
Price To Sales (TTM)
8.33
Price To Book (MRQ)
5.58
Price To Cash Flow (TTM)
27.67
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
15.81
Return on Equity (TTM)
15.04

Latest News

Latest News

BRIEF-Atrion Q1 Earnings Per Share $4.57

* Q1 EARNINGS PER SHARE $4.57 Source text for Eikon: Further company coverage:

BRIEF-Atrion Reports Q4 Earnings Per Share $4.66

* ATRION REPORTS 2017 RESULTS FOR FOURTH QUARTER AND FULL YEAR

BRIEF-Atrion reports Q3 earnings per share $4.29

* Q3 revenue $37.9 million versus $37.8 million Source text for Eikon: Further company coverage:

BRIEF-Atrion increases quarterly cash dividend by 14 pct

* Atrion Corporation increases quarterly cash dividend by 14%

BRIEF-Atrion Q2 earnings per share $5.40

* Q2 revenue $36.2 million versus $36.1 million Source text for Eikon: Further company coverage:

BRIEF-Atrion Q1 earnings per share $5.36

* Q1 revenue $38.5 million versus $36.2 million Source text for Eikon: Further company coverage:

BRIEF-Atrion on Feb. 28, Co entered into credit agreement with Wells Fargo Bank, National Association as lender

* Atrion - on february 28, 2017, co entered into credit agreement with wells fargo bank, national association, as lender

BRIEF-Atrion reports Q4 earnings per share $3.00

* Q4 revenue $33.3 million versus $32.4 million Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up